Latest Health News

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.

Australian Agricultural Company Limited (AACo) reported a record first-half operating profit of $39.8 million, boosted by higher beef and cattle prices and volumes, alongside strategic investments in feedlot expansion and carbon projects.

EVZ Limited has issued earnings guidance for the first half of FY2026, forecasting revenue between $60 million and $65 million and a notable rise in EBITDA, reflecting operational improvements.

The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its women’s and men’s health products Dyspro™ and Libbo™.

Tasmea Limited has announced the acquisition of WorkPac Group for up to A$60.7 million, significantly enhancing its workforce solutions capabilities and positioning the company for growth amid Australia's skilled labour shortages.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

LGI Limited reported robust FY25 results with a 14% rise in EBITDA and secured six new contracts, positioning the company for a 25-30% EBITDA increase in FY26. Key project completions and expansions underpin this momentum.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

OMG Group has inked a five-year exclusive distribution agreement with SANDAI, a premium Japanese matcha producer, positioning itself to capture significant growth in Australia’s expanding matcha market.